<SEC-DOCUMENT>0000059478-22-000248.txt : 20221101
<SEC-HEADER>0000059478-22-000248.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101070347
ACCESSION NUMBER:		0000059478-22-000248
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221101
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		221348460

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lly-20221101.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a1698562-7e12-441d-b3f7-25fc34bd0f18,g:96d279b9-f5ff-4d23-9ef6-231fe292dc22,d:ca917e3bb79e43ab806989fc08ac113f--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:lly="http://www.lilly.com/20221101" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lly-20221101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl80L2ZyYWc6NDViNTI3ZWIxZGYyNDQzM2JlMjI0YmY0NjRjMzQ2ZGQvdGFibGU6YmQyN2FhOWU4NjllNDkwNzk2MmIwYTgzZjdlOTk5ODkvdGFibGVyYW5nZTpiZDI3YWE5ZTg2OWU0OTA3OTYyYjBhODNmN2U5OTk4OV8yLTEtMS0xLTE1OTU1MQ_7102fcb9-83d5-4721-8f83-cd86d2189407">0000059478</ix:nonNumeric><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl80L2ZyYWc6NDViNTI3ZWIxZGYyNDQzM2JlMjI0YmY0NjRjMzQ2ZGQvdGFibGU6YmQyN2FhOWU4NjllNDkwNzk2MmIwYTgzZjdlOTk5ODkvdGFibGVyYW5nZTpiZDI3YWE5ZTg2OWU0OTA3OTYyYjBhODNmN2U5OTk4OV81LTEtMS0xLTE1OTU1MQ_daffb7ee-8079-43b5-ab0b-7a057b1cf9ee">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lly-20221101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if91f3e5334174e1f83766d429987c39e_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ica917e3bb79e43ab806989fc08ac113f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg1_090d1364-9878-4786-b7b0-65b187276702">8-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:2.2pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:13.2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xNTk_357f041e-efb9-41c8-8862-265929f470e6">November 1, 2022</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg2_4946831b-11a3-4d38-b12e-1e18564053a3">ELI LILLY AND COMPANY</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (Exact Name of Registrant as Specified in its Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:26.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.360%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.978%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6ZTE5MmNmM2M2YmVjNDExYWJmNTAxMDFhZmEzNmYwYTEvdGFibGVyYW5nZTplMTkyY2YzYzZiZWM0MTFhYmY1MDEwMWFmYTM2ZjBhMV8wLTAtMS0xLTE1OTU1MQ_80631658-2fa4-46fd-8f30-8153899f626a">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6ZTE5MmNmM2M2YmVjNDExYWJmNTAxMDFhZmEzNmYwYTEvdGFibGVyYW5nZTplMTkyY2YzYzZiZWM0MTFhYmY1MDEwMWFmYTM2ZjBhMV8wLTItMS0xLTE1OTU1MQ_44ed8091-8477-4a05-aa76-5953ff2ea133">001-06351</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6ZTE5MmNmM2M2YmVjNDExYWJmNTAxMDFhZmEzNmYwYTEvdGFibGVyYW5nZTplMTkyY2YzYzZiZWM0MTFhYmY1MDEwMWFmYTM2ZjBhMV8wLTQtMS0xLTE1OTU1MQ_792f45b2-3b54-4081-9616-663df6023556">35-0470950</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:21.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8wLTAtMS0xLTE1OTU1MQ_dc6b0d25-8eaf-4097-8543-d9e884f25597">Lilly Corporate Center</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8xLTAtMS0xLTE1OTU1MQ_171b3d79-1ea8-430f-8eab-7ad379647c85">Indianapolis,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8xLTEtMS0xLTE1OTU1MQ_cb0325cf-4a74-41fe-9748-9c2ffaa0d03b">Indiana</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8xLTItMS0xLTE1OTU1MQ_578f57e3-1149-4b44-9ac6-5748f9359690">46285</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg3_4cded068-0a5d-49b7-b357-eea52fab644a">317</ix:nonNumeric>) <ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg4_0f831128-9b47-4762-a67d-c2efff94aac6">276-2000</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> (Former Name or Former Address, if Changed Since Last Report.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:13.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2.):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NTBiY2JjMDUzODcwNGNhOThiNjRmMTUzZWM1Y2Y2YzUvdGFibGVyYW5nZTo1MGJjYmMwNTM4NzA0Y2E5OGI2NGYxNTNlYzVjZjZjNV8wLTAtMS0xLTE1OTU1MQ_4d2df7e8-773d-4ab3-8461-ad9d12ba2a2a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.130%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzBhZGRhOTdkZTgwNGVlNDljZjI1YWZhNTNjYjZhZTcvdGFibGVyYW5nZTo3MGFkZGE5N2RlODA0ZWU0OWNmMjVhZmE1M2NiNmFlN18wLTAtMS0xLTE1OTU1MQ_04777cac-0e9b-47d5-8b90-60f35ed35d11">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6MzExYTcyM2VjZTM2NDAyZmFiOWJjNzdjZTk5MGNhYzUvdGFibGVyYW5nZTozMTFhNzIzZWNlMzY0MDJmYWI5YmM3N2NlOTkwY2FjNV8wLTAtMS0xLTE1OTU1MQ_ece5ed03-a862-4539-bd71-c88f5be96ef2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:2.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NGQ1MDBkZmIzNzJiNGM1ZTgwMzc3NzU4ZDFhY2UyMjAvdGFibGVyYW5nZTo0ZDUwMGRmYjM3MmI0YzVlODAzNzc3NThkMWFjZTIyMF8wLTAtMS0xLTE1OTU1MQ_5c46353b-015a-4d4d-b6d6-9e69edfe8418">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xLTAtMS0xLTE1OTU1MQ_e43c8ab6-187c-4089-b647-603e2284a20e">Common Stock (no par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xLTItMS0xLTE1OTU1MQ_f7215f31-b9c9-428e-8118-6f20c0c613e9">LLY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xLTQtMS0xLTE1OTU1MQ_f472e356-7935-4fb2-92bf-b630d5d341fa">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8yLTAtMS0xLTE1OTU1MQ_1832c58e-a581-4c1e-a4f2-544613245e25">7 1/8% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8yLTItMS0xLTE1OTU1MQ_dabfae72-ebf5-49cd-8732-040cbd839ba7">LLY25</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8yLTQtMS0xLTE1OTU1MQ_0f3ebd20-1360-4c87-9f44-14c3c8609410">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8zLTAtMS0xLTE1OTU1MQ_e29633e9-1505-49a8-bf7e-297c69921510">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8zLTItMS0xLTE1OTU1MQ_433392e8-191e-46eb-97c9-298168de444f">LLY26</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8zLTQtMS0xLTE1OTU1MQ_8707c7ff-b8af-467f-95cb-618a333abed6">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if91f3e5334174e1f83766d429987c39e_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV80LTAtMS0xLTE1OTU1MQ_147c660b-8fc6-46e6-9cf4-cae5298c7738">2.125% Notes due 2030</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if91f3e5334174e1f83766d429987c39e_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV80LTItMS0xLTE1OTU1MQ_fa0dbf96-ed45-45d5-ac8f-d7cceccc60c5">LLY30</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if91f3e5334174e1f83766d429987c39e_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV80LTQtMS0xLTE1OTU1MQ_94420cbc-e54c-436b-95b8-9fed5a4808d8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV81LTAtMS0xLTE1OTU1MQ_ffdf3854-6211-48ba-920e-58d01767d68d">0.625% Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV81LTItMS0xLTE1OTU1MQ_4c381bab-2d95-474a-893a-15f5489e47dc">LLY31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV81LTQtMS0xLTE1OTU1MQ_6a9cc135-38fc-40d3-9065-a18f93fdf7f9">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV82LTAtMS0xLTE1OTU1MQ_80563eda-5a20-4ddf-ba0f-9217f4f2368b">0.500% Notes due 2033</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV82LTItMS0xLTE1OTU1MQ_2731b356-b828-4475-b389-e8b09a8493b9">LLY33</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV82LTQtMS0xLTE1OTU1MQ_272eb06f-868b-4493-8670-6b5138be7288">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV83LTAtMS0xLTE1OTU1MQ_2b9ba470-ec09-427a-9834-0970cfdb8240">6.77% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV83LTItMS0xLTE1OTU1MQ_de6a0f24-b3d6-454c-b722-2b8a706d8a45">LLY36</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV83LTQtMS0xLTE1OTU1MQ_9a4a4810-0e91-47c1-a63f-7d912f2f3ed9">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV84LTAtMS0xLTE1OTU1MQ_7211a67f-8948-473d-8290-0a1605ddcf1c">1.625% Notes due 2043</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV84LTItMS0xLTE1OTU1MQ_5a86633f-7f2a-4678-8bbe-ed332a9d4129">LLY43</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV84LTQtMS0xLTE1OTU1MQ_cf020ac7-fa2b-448c-bc3f-d51c9f04f82c">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV85LTAtMS0xLTE1OTU1MQ_a8d94290-4518-4465-a504-d9a588748a96">1.700% Notes due 2049</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV85LTItMS0xLTE1OTU1MQ_df75e0b1-a57a-41ae-a34e-31eb4c01644d">LLY49A</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV85LTQtMS0xLTE1OTU1MQ_9b5e5d08-0051-41fd-a111-9316d9bb2971">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMC0wLTEtMS0xNTk1NTE_9ac3c1f2-b9c4-4c49-8c3c-648130c30e6c">1.125% Notes due 2051</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMC0yLTEtMS0xNTk1NTE_550ca458-dbfd-43f1-b2d7-35f6012c18ed">LLY51</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMC00LTEtMS0xNTk1NTE_11803921-0321-4707-b08c-d4d71fb0d9e7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMS0wLTEtMS0xNTk1NTE_42fc72be-ec91-4b74-a5d4-738cfc82114c">1.375% Notes due 2061</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMS0yLTEtMS0xNTk1NTE_1ca3df82-97db-44ba-809a-bad2febfbbce">LLY61</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMS00LTEtMS0xNTk1NTE_17188bbe-a694-4109-b218-37116f593fc7">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg5_e6f8e183-1fe1-40fb-af96-14c7afce9a9b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="ica917e3bb79e43ab806989fc08ac113f_7"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.  Results of Operations and Financial Condition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated November&#160;1, 2022, announcing the financial results of Eli Lilly and Company for the quarter ended September 30, 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 9.01.  Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.745%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q322lillysalesandearningsp.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q322lillysalesandearningsp.htm">Press Release of Eli Lilly and Company, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q322lillysalesandearningsp.htm">November 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q322lillysalesandearningsp.htm">, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.666%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ELI LILLY AND COMPANY</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Donald A. Zakrowski</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senior Vice President, Finance, and <br/>Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">November 1, 2022</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>lly-20221101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a1698562-7e12-441d-b3f7-25fc34bd0f18,g:96d279b9-f5ff-4d23-9ef6-231fe292dc22-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20221101" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lilly.com/20221101">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20221101_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.lilly.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lly_A625Notesdue2031Member" abstract="true" name="A625Notesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.700Notesdue2049Member" abstract="true" name="A1.700Notesdue2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A500NotesDue2033Member" abstract="true" name="A500NotesDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1.625NotesDueJune22026Member" abstract="true" name="A1.625NotesDueJune22026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1375NotesDue2061Member" abstract="true" name="A1375NotesDue2061Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A6.77NotesDueJanuary12036Member" abstract="true" name="A6.77NotesDueJanuary12036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1625NotesDue2043Member" abstract="true" name="A1625NotesDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A1125NotesDue2051Member" abstract="true" name="A1125NotesDue2051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A2.125NotesDueJune32030Member" abstract="true" name="A2.125NotesDueJune32030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lly_A718NotesDueJune12025Member" abstract="true" name="A718NotesDueJune12025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>lly-20221101_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a1698562-7e12-441d-b3f7-25fc34bd0f18,g:96d279b9-f5ff-4d23-9ef6-231fe292dc22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20221101.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended" id="i4462ab6abe864406a9142620557d238f_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_373cd1da-783c-4550-b266-62e627bd98a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_DocumentType_373cd1da-783c-4550-b266-62e627bd98a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a5a3800d-9fe4-426d-90ed-cd7dbd822371" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_DocumentPeriodEndDate_a5a3800d-9fe4-426d-90ed-cd7dbd822371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b6aac879-6a70-4f1c-bc78-39d792695b63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b6aac879-6a70-4f1c-bc78-39d792695b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b2ec8a1e-2c8d-437e-a6e3-36cbbdf9c3b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityFileNumber_b2ec8a1e-2c8d-437e-a6e3-36cbbdf9c3b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_416b0d4a-ce6b-4cc1-b2d0-d244b7ff2132" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityTaxIdentificationNumber_416b0d4a-ce6b-4cc1-b2d0-d244b7ff2132" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8a83f280-dc63-4752-b64e-9c6c6a43ae01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressAddressLine1_8a83f280-dc63-4752-b64e-9c6c6a43ae01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bc1d2790-21d6-462f-ab1b-d29858a0a175" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressCityOrTown_bc1d2790-21d6-462f-ab1b-d29858a0a175" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_52ff8c44-c094-4050-96ed-ca119ac9ed6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressStateOrProvince_52ff8c44-c094-4050-96ed-ca119ac9ed6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f34a848d-01c0-464c-8270-ec749326733c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressPostalZipCode_f34a848d-01c0-464c-8270-ec749326733c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_25fbbd49-4442-4ec0-89a5-ac2351dfd267" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_CityAreaCode_25fbbd49-4442-4ec0-89a5-ac2351dfd267" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bd3a5381-4e97-46e3-a68d-2cf487d594fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_LocalPhoneNumber_bd3a5381-4e97-46e3-a68d-2cf487d594fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e1eab2e7-acbc-4c18-bb71-728489c8e14c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_WrittenCommunications_e1eab2e7-acbc-4c18-bb71-728489c8e14c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4269da80-61dc-412f-bdb2-5ad25698f5d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_SolicitingMaterial_4269da80-61dc-412f-bdb2-5ad25698f5d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_06833618-7ba3-4468-99bf-f2508377e83b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_PreCommencementTenderOffer_06833618-7ba3-4468-99bf-f2508377e83b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3ebafa08-9edf-4afd-81d5-ffbb133b9e20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3ebafa08-9edf-4afd-81d5-ffbb133b9e20" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c980ac8d-582d-411d-83ac-07eec40a48eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityEmergingGrowthCompany_c980ac8d-582d-411d-83ac-07eec40a48eb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_abd3376b-42be-424b-aa17-148c372cc756" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_Security12bTitle_abd3376b-42be-424b-aa17-148c372cc756" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d92e4c59-6a1d-4069-9582-1c76353cc085" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_TradingSymbol_d92e4c59-6a1d-4069-9582-1c76353cc085" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_12c2d966-3edc-4875-aeb5-2d00f1e119eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_SecurityExchangeName_12c2d966-3edc-4875-aeb5-2d00f1e119eb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_12eb43eb-b1a6-4d25-88fe-e0f1dfd871f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityRegistrantName_12eb43eb-b1a6-4d25-88fe-e0f1dfd871f7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f10fc6ba-e833-4eb1-a640-ace20bf1aacd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityCentralIndexKey_f10fc6ba-e833-4eb1-a640-ace20bf1aacd" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24fff332-a172-4608-9d60-59ca8a429530" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_AmendmentFlag_24fff332-a172-4608-9d60-59ca8a429530" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_09222354-b051-4b03-88c7-e56646ea2fc2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:to="loc_us-gaap_ClassOfStockDomain_09222354-b051-4b03-88c7-e56646ea2fc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:to="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f4ccbde2-4da0-4120-a51c-be2076eda62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_us-gaap_CommonClassAMember_f4ccbde2-4da0-4120-a51c-be2076eda62b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_f433f5d9-0539-4533-8172-100925e7a91f" xlink:href="lly-20221101.xsd#lly_A718NotesDueJune12025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A718NotesDueJune12025Member_f433f5d9-0539-4533-8172-100925e7a91f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_f947c4b5-373f-4ec1-a4dc-54b034555dbb" xlink:href="lly-20221101.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1.625NotesDueJune22026Member_f947c4b5-373f-4ec1-a4dc-54b034555dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_44f04c76-9dd2-4b9e-9f71-53425eea086e" xlink:href="lly-20221101.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A2.125NotesDueJune32030Member_44f04c76-9dd2-4b9e-9f71-53425eea086e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_44dadc6c-3472-4437-9cfa-348ac5b4bd76" xlink:href="lly-20221101.xsd#lly_A625Notesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A625Notesdue2031Member_44dadc6c-3472-4437-9cfa-348ac5b4bd76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_468b60c7-0c30-45a0-a48f-bf9158d35394" xlink:href="lly-20221101.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_468b60c7-0c30-45a0-a48f-bf9158d35394" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_faaa4c98-3e11-4ee3-a0be-2f29e4320e43" xlink:href="lly-20221101.xsd#lly_A1.700Notesdue2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1.700Notesdue2049Member_faaa4c98-3e11-4ee3-a0be-2f29e4320e43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_8b1d38fc-af96-44ea-a801-40ef9246a5dd" xlink:href="lly-20221101.xsd#lly_A500NotesDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A500NotesDue2033Member_8b1d38fc-af96-44ea-a801-40ef9246a5dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_33447157-15a7-481f-96ac-c5a43fc0a2d8" xlink:href="lly-20221101.xsd#lly_A1625NotesDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1625NotesDue2043Member_33447157-15a7-481f-96ac-c5a43fc0a2d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_c58982d6-f172-4ef3-9cd5-bb717a79f059" xlink:href="lly-20221101.xsd#lly_A1125NotesDue2051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1125NotesDue2051Member_c58982d6-f172-4ef3-9cd5-bb717a79f059" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_01f8503f-c7f8-4df8-8867-9c26d91603f8" xlink:href="lly-20221101.xsd#lly_A1375NotesDue2061Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1375NotesDue2061Member_01f8503f-c7f8-4df8-8867-9c26d91603f8" xlink:type="arc" order="10"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>lly-20221101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a1698562-7e12-441d-b3f7-25fc34bd0f18,g:96d279b9-f5ff-4d23-9ef6-231fe292dc22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_6e2ee565-4fa4-4294-8f14-8f79f85a14f3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b2116d11-594c-4b5f-afad-0b1254a51dda_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1125NotesDue2051Member_38296b76-1898-433e-b30a-343d56b95a64_terseLabel_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_label_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051 [Member]</link:label>
    <link:label id="lab_lly_A1125NotesDue2051Member_documentation_en-US" xlink:label="lab_lly_A1125NotesDue2051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Notes due 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member" xlink:href="lly-20221101.xsd#lly_A1125NotesDue2051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1125NotesDue2051Member" xlink:to="lab_lly_A1125NotesDue2051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1625NotesDue2043Member_b49bd9d9-74ae-453a-8b9b-334d9072dbfd_terseLabel_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_label_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043 [Member]</link:label>
    <link:label id="lab_lly_A1625NotesDue2043Member_documentation_en-US" xlink:label="lab_lly_A1625NotesDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625%&#160;Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member" xlink:href="lly-20221101.xsd#lly_A1625NotesDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1625NotesDue2043Member" xlink:to="lab_lly_A1625NotesDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_995254e7-fc1d-408e-8c6a-d6f0faf5bd70_terseLabel_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes due 2026</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_label_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:label id="lab_lly_A1.625NotesDueJune22026Member_documentation_en-US" xlink:label="lab_lly_A1.625NotesDueJune22026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due June 2, 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member" xlink:href="lly-20221101.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.625NotesDueJune22026Member" xlink:to="lab_lly_A1.625NotesDueJune22026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f0eb679b-e443-4d59-b383-314b168d1859_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6a600415-137e-4d19-a811-fcc1c18b4780_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_947d4b87-e249-49b1-98b4-4ae82714e469_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1.700Notesdue2049Member_86b9be0a-5f63-4174-a549-f94b4fddda1d_terseLabel_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_label_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:label id="lab_lly_A1.700Notesdue2049Member_documentation_en-US" xlink:label="lab_lly_A1.700Notesdue2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.700% Notes due 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member" xlink:href="lly-20221101.xsd#lly_A1.700Notesdue2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1.700Notesdue2049Member" xlink:to="lab_lly_A1.700Notesdue2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_03106baa-7864-4d0a-a29c-77ce25980dd2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A1375NotesDue2061Member_5e2999ba-c2db-4eb7-8942-c5c9262d8894_terseLabel_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_label_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061 [Member]</link:label>
    <link:label id="lab_lly_A1375NotesDue2061Member_documentation_en-US" xlink:label="lab_lly_A1375NotesDue2061Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2061</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member" xlink:href="lly-20221101.xsd#lly_A1375NotesDue2061Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A1375NotesDue2061Member" xlink:to="lab_lly_A1375NotesDue2061Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_136fbe37-cdd2-45da-971d-4a602deb150a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9aafcbc6-2617-46fc-90bf-31f5fc147210_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_73f73a3f-f8ae-4e9e-ad05-898acb6507a0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_d9c5b3c6-f264-402b-bd13-997447237010_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_d4672001-3ddb-4ea1-a044-11a5d75f4329_terseLabel_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77% Notes due 2036</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_label_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:label id="lab_lly_A6.77NotesDueJanuary12036Member_documentation_en-US" xlink:label="lab_lly_A6.77NotesDueJanuary12036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.77%&#160;Notes Due January&#160;1, 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member" xlink:href="lly-20221101.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A6.77NotesDueJanuary12036Member" xlink:to="lab_lly_A6.77NotesDueJanuary12036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A718NotesDueJune12025Member_0a7d5e6d-310d-4c8a-9e77-d25ee5d20f99_terseLabel_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes due 2025</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_label_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:label id="lab_lly_A718NotesDueJune12025Member_documentation_en-US" xlink:label="lab_lly_A718NotesDueJune12025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7 1/8% Notes Due June&#160;1, 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member" xlink:href="lly-20221101.xsd#lly_A718NotesDueJune12025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A718NotesDueJune12025Member" xlink:to="lab_lly_A718NotesDueJune12025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_27ad080d-6fc2-4e31-ae72-681ff12bdf90_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_ad822c3f-dee0-41f1-98ff-3f1506e18c1e_terseLabel_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes due 2030</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_label_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:label id="lab_lly_A2.125NotesDueJune32030Member_documentation_en-US" xlink:label="lab_lly_A2.125NotesDueJune32030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.125% Notes Due June 3, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member" xlink:href="lly-20221101.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A2.125NotesDueJune32030Member" xlink:to="lab_lly_A2.125NotesDueJune32030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f4bd2dd3-700d-4479-bc89-219b35b4ce51_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e2ea326a-c084-4b9b-8d55-5d73c0cead68_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_cbc695da-33d6-4376-8683-b09d1bca1bf5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_31e548fc-d2e0-4f8d-b946-0769566bdb0b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A500NotesDue2033Member_2064065d-61d7-46de-9c9f-9dc086a7337d_terseLabel_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_label_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.500% Notes due 2033 [Member]</link:label>
    <link:label id="lab_lly_A500NotesDue2033Member_documentation_en-US" xlink:label="lab_lly_A500NotesDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member" xlink:href="lly-20221101.xsd#lly_A500NotesDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A500NotesDue2033Member" xlink:to="lab_lly_A500NotesDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a2109d04-c8e9-4079-bd41-fe2b54eef5e6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_0068240a-497a-49af-acf0-7c4fb35f43a5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0408395e-020f-4d9f-b127-ddf57d91a7f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8a92ad0d-d118-4b8f-8ad5-758c1c33f58c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e14f5e4d-c4bd-4433-8ea3-2e52e25bd969_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_de2ef999-9556-4ac3-b754-f25b78bdf515_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock (no par value)</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_360803de-26b3-43fa-8466-e62046b59c40_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_f64ead86-c266-4403-933f-1fd1117177a4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lly_A625Notesdue2031Member_a6c2d915-c55a-41a4-b3ce-fc9b2ff2d80e_terseLabel_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.625% Notes due 2031</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_label_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:label id="lab_lly_A625Notesdue2031Member_documentation_en-US" xlink:label="lab_lly_A625Notesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">.625% Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member" xlink:href="lly-20221101.xsd#lly_A625Notesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lly_A625Notesdue2031Member" xlink:to="lab_lly_A625Notesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e42bbf73-7b57-4ace-a605-fbc89f4c4b67_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_dc9a40b5-cc41-4b73-8fc3-5616cc3c2fdf_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9d735d0c-400e-4640-bb42-cc346a83b4b5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_126c12a3-8e58-45b7-a3a4-ced356550fdb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_3fb1ddc5-186e-43da-b0d8-91634f36599d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>lly-20221101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a1698562-7e12-441d-b3f7-25fc34bd0f18,g:96d279b9-f5ff-4d23-9ef6-231fe292dc22-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com/role/CoverPage" xlink:type="simple" xlink:href="lly-20221101.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.lilly.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2fe6ec89-fb0f-4eb6-8849-969aef43f0d8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2fe6ec89-fb0f-4eb6-8849-969aef43f0d8" xlink:to="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:to="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_09222354-b051-4b03-88c7-e56646ea2fc2" xlink:to="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f4ccbde2-4da0-4120-a51c-be2076eda62b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_us-gaap_CommonClassAMember_f4ccbde2-4da0-4120-a51c-be2076eda62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A718NotesDueJune12025Member_f433f5d9-0539-4533-8172-100925e7a91f" xlink:href="lly-20221101.xsd#lly_A718NotesDueJune12025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A718NotesDueJune12025Member_f433f5d9-0539-4533-8172-100925e7a91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.625NotesDueJune22026Member_f947c4b5-373f-4ec1-a4dc-54b034555dbb" xlink:href="lly-20221101.xsd#lly_A1.625NotesDueJune22026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1.625NotesDueJune22026Member_f947c4b5-373f-4ec1-a4dc-54b034555dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A2.125NotesDueJune32030Member_44f04c76-9dd2-4b9e-9f71-53425eea086e" xlink:href="lly-20221101.xsd#lly_A2.125NotesDueJune32030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A2.125NotesDueJune32030Member_44f04c76-9dd2-4b9e-9f71-53425eea086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A625Notesdue2031Member_44dadc6c-3472-4437-9cfa-348ac5b4bd76" xlink:href="lly-20221101.xsd#lly_A625Notesdue2031Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A625Notesdue2031Member_44dadc6c-3472-4437-9cfa-348ac5b4bd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A6.77NotesDueJanuary12036Member_468b60c7-0c30-45a0-a48f-bf9158d35394" xlink:href="lly-20221101.xsd#lly_A6.77NotesDueJanuary12036Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A6.77NotesDueJanuary12036Member_468b60c7-0c30-45a0-a48f-bf9158d35394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1.700Notesdue2049Member_faaa4c98-3e11-4ee3-a0be-2f29e4320e43" xlink:href="lly-20221101.xsd#lly_A1.700Notesdue2049Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1.700Notesdue2049Member_faaa4c98-3e11-4ee3-a0be-2f29e4320e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A500NotesDue2033Member_8b1d38fc-af96-44ea-a801-40ef9246a5dd" xlink:href="lly-20221101.xsd#lly_A500NotesDue2033Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A500NotesDue2033Member_8b1d38fc-af96-44ea-a801-40ef9246a5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1625NotesDue2043Member_33447157-15a7-481f-96ac-c5a43fc0a2d8" xlink:href="lly-20221101.xsd#lly_A1625NotesDue2043Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1625NotesDue2043Member_33447157-15a7-481f-96ac-c5a43fc0a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1125NotesDue2051Member_c58982d6-f172-4ef3-9cd5-bb717a79f059" xlink:href="lly-20221101.xsd#lly_A1125NotesDue2051Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1125NotesDue2051Member_c58982d6-f172-4ef3-9cd5-bb717a79f059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lly_A1375NotesDue2061Member_01f8503f-c7f8-4df8-8867-9c26d91603f8" xlink:href="lly-20221101.xsd#lly_A1375NotesDue2061Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b30f6795-8259-4b85-9314-dcfa8358ae62" xlink:to="loc_lly_A1375NotesDue2061Member_01f8503f-c7f8-4df8-8867-9c26d91603f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_27ae1f77-0df3-4e3c-8a98-f7a78dc0d267" xlink:to="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_373cd1da-783c-4550-b266-62e627bd98a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_DocumentType_373cd1da-783c-4550-b266-62e627bd98a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_a5a3800d-9fe4-426d-90ed-cd7dbd822371" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_DocumentPeriodEndDate_a5a3800d-9fe4-426d-90ed-cd7dbd822371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b6aac879-6a70-4f1c-bc78-39d792695b63" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b6aac879-6a70-4f1c-bc78-39d792695b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b2ec8a1e-2c8d-437e-a6e3-36cbbdf9c3b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityFileNumber_b2ec8a1e-2c8d-437e-a6e3-36cbbdf9c3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_416b0d4a-ce6b-4cc1-b2d0-d244b7ff2132" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityTaxIdentificationNumber_416b0d4a-ce6b-4cc1-b2d0-d244b7ff2132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8a83f280-dc63-4752-b64e-9c6c6a43ae01" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressAddressLine1_8a83f280-dc63-4752-b64e-9c6c6a43ae01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bc1d2790-21d6-462f-ab1b-d29858a0a175" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressCityOrTown_bc1d2790-21d6-462f-ab1b-d29858a0a175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_52ff8c44-c094-4050-96ed-ca119ac9ed6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressStateOrProvince_52ff8c44-c094-4050-96ed-ca119ac9ed6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f34a848d-01c0-464c-8270-ec749326733c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityAddressPostalZipCode_f34a848d-01c0-464c-8270-ec749326733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_25fbbd49-4442-4ec0-89a5-ac2351dfd267" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_CityAreaCode_25fbbd49-4442-4ec0-89a5-ac2351dfd267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bd3a5381-4e97-46e3-a68d-2cf487d594fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_LocalPhoneNumber_bd3a5381-4e97-46e3-a68d-2cf487d594fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_e1eab2e7-acbc-4c18-bb71-728489c8e14c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_WrittenCommunications_e1eab2e7-acbc-4c18-bb71-728489c8e14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_4269da80-61dc-412f-bdb2-5ad25698f5d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_SolicitingMaterial_4269da80-61dc-412f-bdb2-5ad25698f5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_06833618-7ba3-4468-99bf-f2508377e83b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_PreCommencementTenderOffer_06833618-7ba3-4468-99bf-f2508377e83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_3ebafa08-9edf-4afd-81d5-ffbb133b9e20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_3ebafa08-9edf-4afd-81d5-ffbb133b9e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c980ac8d-582d-411d-83ac-07eec40a48eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityEmergingGrowthCompany_c980ac8d-582d-411d-83ac-07eec40a48eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_abd3376b-42be-424b-aa17-148c372cc756" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_Security12bTitle_abd3376b-42be-424b-aa17-148c372cc756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d92e4c59-6a1d-4069-9582-1c76353cc085" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_TradingSymbol_d92e4c59-6a1d-4069-9582-1c76353cc085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_12c2d966-3edc-4875-aeb5-2d00f1e119eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_SecurityExchangeName_12c2d966-3edc-4875-aeb5-2d00f1e119eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_12eb43eb-b1a6-4d25-88fe-e0f1dfd871f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityRegistrantName_12eb43eb-b1a6-4d25-88fe-e0f1dfd871f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f10fc6ba-e833-4eb1-a640-ace20bf1aacd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_EntityCentralIndexKey_f10fc6ba-e833-4eb1-a640-ace20bf1aacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24fff332-a172-4608-9d60-59ca8a429530" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d05eec2a-3441-4e55-982f-ba0f9e9d8bb6" xlink:to="loc_dei_AmendmentFlag_24fff332-a172-4608-9d60-59ca8a429530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>logoa31.jpg
<TEXT>
begin 644 logoa31.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P *N\.7.;BYMSQXINDX\WC_ )=XS_JTZ.?GY_=^7]'?\' /_!4K_A#;&\^
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MQCJQ3BFI*.JGHI1<79Z]-;K6ZMK^EU%%%?8G\VA1110 4444 %%%% !1110
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M[XA_MM+<>'/#ZMX#^&]T?(N=+MIQ]NUB+'6ZG_N?],8\1_.0_F8!KR?]A/\
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M!M=#\,V,M_=3J 3L3G8@_B=SA47N2.]<1^R'^P3\+OV)=!OK7X>^&_[+FU3
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M5M7:2=^H_P""Q?\ P67O?VN]5O/AS\/+V[T_X8V5SMN[U6,,_BB6-NI_N6W
M*)_']]_[B>8?\$GO^"8&N?\ !0CXK"\U);K2/A?X:N -9U11M-W+_K!90_\
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M>Z/<Z9':M-:W-K]JMQ/;^>,>?$?XTKX//N+G53H8&Z766S?IU2\^I_5GA/\
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M;5ET'X:^#=.@M[;0M.8B#4;L?O)[VXDX\Z629Y).?W<?1.=[OX?7ZW?\$'_
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MQ1VNP_N4C_@V=_GSOYK@=2FN-1>XU"\:ZNKB\N9?.N9_W@GE^^_[S^*3Y_\
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MIO\ PK6^NO"O_"-W$6HWWBZ%G6#0$!P?NX\R=_GV0_\ +3G.Q-\@B_X)Q?\
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M\[(ER,EXB4^Z2A)?97YMZ]^P!\<_"^I?V?>_!OXEI= ]!X8O)@?^N;I'L?\
MX!7]45%<N8<'X3$U'4@W!O>VWW=#W>$/I(<0Y-@88#%4XXF,%:,IN2G;HFT[
M2MT;7-;=O0_F;^$'_!'']I;XTWUO]C^%'B#1[53S<^( -'%O_P  G\N3_OB,
MU]]?L@_\&S6A^$[^UU7XS>)AXJF!!?1-"\RTL^O/F79Q,XQ_<2 @_P 9K]:J
M*TP7!^ H/FFG-^>WW*QR<3?2-XLS6F\/AI1PT'_S[3Y__ Y-M>3BHM=S\V?^
M"QW_  2LN/CA^S-X*M?@MX;TJSNOA?=77V7PUIXBLH[JTNA'YYC'"/.)8(7Q
M)S)B0_.^$D_'^']@/XZ7>H_V>GP<^*GVKT_X16^X_P#(>*_JFK\E?^"[G_!6
MUO 5OJ7P1^&NHDZY=0F#Q1J\ Q_9\3_\N,+CCS7'^LD'$?W!\^\1\/$V2X&,
M7C:LG'965M6E9)?):^6I]7X&^)W%<ZD.%\!0CB$W*7/-R7LXRES3E-INZYI-
MI64I2E:[;5OQU\3:!=>$?$MUIUXJQWEC<&"=5G2=1(G'WT^1Z]\_X)Q?\$[?
M%7_!0KXRKHVF[]+\,Z81-KVN?9RT6G19_P!7'Q\\TG\"=L$G %<[^PW^Q7XM
M_;Q^.=GX'\,QO;0\7&K:G- 3;Z3;=))9/Y(G&]SVZC^CK]E/]E3PG^QK\%])
M\!^"[0VNDZ?\UQ-.P:ZU*X?;ON)I,?/(Q![;0 J($1$0?,\-\/O'5/:U5:DG
MKY^2_4_;/&KQ@APKA/[-P#4L=46FUJ:VYY)MJ[UY(OOS/1*^S^SI^SKX5_96
M^%&F^"?!.F#2]"TT<9&Z6YD_CEF?J\C]W/\ A7H]%%?KD(1A%1BK)'^>>*Q5
M;$UI8C$2<IR;<I-MMMZMMO5ML****HP"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_BE\1-%^$'PWU[Q
M9XBN4L]'\,V,U_?7!'^HBC0NY_(9I2DDKLNG3G4FJ=)7E)V26[;T27FV?*/_
M  60_P""CMO^P;^SHUKHDV[XC^,A+8Z"KIYGV!>1)>.#Q\F?W8.=\FSAT23'
MX"?#KX?^*OVC_BMIOAO0[.\U[Q1XNU 06ZD^=-<SR.=\LC_F[N_^VY]:[/\
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MHHHK8\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>q322lillysalesandearningsp.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i98ce0abc448f4f99903a91460bfdd3e1_1"></div><div style="min-height:103.68pt;width:100%"><div style="text-align:right"><img alt="logoa31.jpg" src="logoa31.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:112px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Nov. 1, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:100%">For Release&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Immediately</font></div><div><font style="color:#000000;font-family:'DIN-Regular',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Refer to&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Jordan Bishop&#59; jordan.bishop&#64;lilly.com&#59; (317) 473-5712 (Media)</font></div><div style="padding-left:36pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Joe Fletcher&#59; jfletcher&#64;lilly.com&#59; </font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">(317) 296-2884</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> (Investors)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:140%">Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Lilly's revenue in Q3 2022 increased 2%, or 7% on a constant currency basis, primarily driven by volume growth of key growth products, partially offset by lower realized prices and lower Alimta revenue following the entry of generics. Total worldwide volume in Q3 2022 increased 14%. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Strong launch for Mounjaro led to $97.3 million in U.S. revenue in Q3 2022. The company also recognized $86.0 million in Mounjaro revenue related to a sales collaboration agreement for the right to sell and distribute Mounjaro in Japan.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.15pt">Pipeline advancements included the </font><font style="color:#242424;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">FDA granting Fast Track designation for tirzepatide in obesity, regulatory approvals in Europe and Japan for Mounjaro in type 2 diabetes, and </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">the submission of lebrikizumab </font><font style="color:#242424;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">for moderate-to-severe atopic dermatitis in the U.S. and European Union.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Key growth products - consisting of Verzenio, Trulicity, Mounjaro, Jardiance, Taltz, Emgality, Retevmo, Cyramza, Tyvyt and Olumiant - grew 19% and represented 70% of revenue in Q3 2022, excluding revenue from COVID-19 antibodies.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">Q3 2022 EPS increased 32% to $1.61 on a reported basis and increased 12% to $1.98 on a non-GAAP basis. Q3 2022 reported and non-GAAP EPS are both inclusive of $0.06 of acquired IPR&#38;D and development milestone charges. </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.76pt">2022</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> EPS guidance updated to be in the range of $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis, both inclusive of $0.67 of acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">INDIANAPOLIS, Nov. 1, 2022 - Eli Lilly and Company (NYSE&#58; LLY) today announced its financial results for the third quarter of 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:164%">&#34;Lilly delivered another solid quarter with pipeline advancements across the portfolio, continued growth of key products, and impressive uptake from our recently launched medicine, Mounjaro, for type 2 diabetes,&#34; said David A. Ricks, Lilly's chair and CEO. &#34;With four more launches expected by the end of next year and a potential major new indication for tirzepatide, Lilly continues to make progress for patients with unaddressed medical needs through our significant commitment to invest </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Eli Lilly and Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> &#124; Lilly Corporate Center &#124; Indianapolis, Indiana 46285 &#124; U.S.A.</font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:164%">in R&#38;D, welcome the best talent, and turn breakthroughs in our labs into medicines for people around the world.&#34;</font></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_4"></div><div><font style="color:#242424;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#242424;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">The U.S. Food and Drug Administration (FDA) granting Fast Track designation for tirzepatide in obesity or overweight with weight-related comorbidities. Lilly plans to initiate a rolling submission in 2022 and complete the submission shortly after SURMOUNT-2 data is available, which is expected in April 2023&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Regulatory authorities in Europe and Japan approving Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> for the treatment of adults with type 2 diabetes&#59; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#212121;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#242424;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">The submission of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis to the FDA and submission by Almirall in the European Union&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">The FDA granting accelerated approval for Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in adults with advanced or metastatic solid tumors with a RET gene fusion regardless of tumor type, and simultaneously granting traditional approval in adults with locally advanced or metastatic non-small cell lung cancer with a RET gene fusion, as detected by an FDA-approved test&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">The commercial availability of bebtelovimab for purchase by states, hospitals and certain other providers&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:13.76pt">Supplying an additional 60,000 doses of bebtelovimab to the U.S. government in Q3 2022 for approximately $110 million to be used for financially vulnerable patients&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">The entry into a definitive agreement to acquire Akouos, a precision genetic medicine company developing first-in-class adeno-associated viral vector-based gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">Announcing that Stephen Fry, Lilly&#8217;s executive vice president, human resources and diversity, will retire at the end of 2022 and Eric Dozier, senior vice president and chief commercial officer for Loxo&#64;Lilly, will succeed him&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:180%">&#8226;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;padding-left:14.15pt">Publishing of Lilly's inaugural Sustainability Bond Allocation and Impact Report that highlights allocation of approximately 128 million euros across a range of projects since the issuance of the sustainability bonds in September 2021.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;2</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For additional information on these and other important public announcements, visit the news section of Lilly's website.</font></div><div><font><br></font></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_7"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Financial Results</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.660%"><tr><td style="width:1.0%"></td><td style="width:46.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.904%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$ in millions, except <br>per share data</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Quarter</font></div></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$6,941.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">$6,772.8</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,451.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,110.1</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">31%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Reported</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.61</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.22</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">Net Income &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,789.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1,614.2</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">11%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">EPS &#8211; Non-GAAP</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.98</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">1.77</font></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:11pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">A discussion of the non-GAAP financial measures is included under &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited).&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Third-Quarter Reported Results</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q3 2022, worldwide revenue was $6.94 billion, an increase of 2% compared with Q3 2021, driven by a 14% increase in volume, partially offset by a 7% decrease due to lower realized prices and a 4% decrease from the unfavorable impact of foreign exchange rates. Key growth products, consisting of Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Mounjaro, Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Retevmo, Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> and Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, grew 19% and represented 70% of revenue for Q3 2022, excluding revenue from COVID-19 antibodies. Excluding revenue from Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, which lost exclusivity in major markets, COVID-19 antibodies, and Olumiant for the treatment of COVID-19, worldwide revenue increased 9% in Q3 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue in the U.S. increased 11% to $4.42 billion, driven by a 15% increase in volume, partially offset by a 4% decrease due to lower realized prices. Excluding revenue from Alimta, COVID-19 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;3</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">antibodies, and Olumiant for the treatment of COVID-19, revenue in the U.S. increased by 20%, primarily driven by volume from key growth products. The lower realized prices in the U.S. were primarily driven by Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">, due to unfavorable segment mix and list price reduction of Insulin Lispro injection.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Revenue outside the U.S. decreased 9% to $2.52 billion, driven by a 12% decrease due to lower realized prices and an 11% decrease from the unfavorable impact of foreign exchange rates, partially offset by a 13% increase in volume. The lower realized prices were primarily driven by the impact of government pricing in China from the National Reimbursement Drug List (NRDL) formulary for certain products, particularly Tyvyt and Verzenio, and volume-based procurement (VBP) for Humalog. The increase in volume outside the U.S. was largely driven by key growth products and the NRDL formulary in China, partially offset by decreased volume for Alimta and Cymbalta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:180%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> resulting from generic competition. Additionally in Q3 2022, the company recognized $86.0 million in Mounjaro revenue related to a sales collaboration agreement with Mitsubishi Tanabe Pharma for the right to sell and distribute Mounjaro in Japan. Excluding revenue from Alimta, COVID-19 antibodies, and Olumiant for the treatment of COVID-19, revenue outside the U.S. decreased by 5%, or an increase of 6% on a constant currency basis.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Gross margin was relatively flat at $5.36 billion in Q3 2022 compared with Q3 2021. Gross margin as a percent of revenue was 77.3%, a decrease of 1.6 percentage points compared with Q3 2021. Gross margin in Q3 2021 </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">included a benefit from the partial reversal of a previous inventory charge related to COVID-19 antibodies. Additionally, in 2022, </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">lower realized prices and increased expenses due to inflation and logistics costs were offset by favorable product mix, including the impact of lower sales of Olumiant for the treatment of COVID-19, and the favorable impact of foreign exchange rates.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q3 2022, research and development expenses increased 6% to $1.80 billion, or 26% of revenue, driven by higher development expenses for late-stage assets, partially offset by the favorable impact of foreign exchange rates and lower development expenses for COVID-19 antibodies.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;4</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Marketing, selling and administrative expenses increased 2% to $1.61 billion in Q3 2022, primarily driven by increased costs associated with the launch of Mounjaro, partially offset by the favorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q3 2022, the company recognized acquired in-process research and development (IPR&#38;D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">and development milestone charges of $62.4 million compared with $177.6 million in Q3 2021. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q3 2022, the company recognized asset impairment, restructuring and other special charges of $206.5 million, primarily related to an intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing. There were no asset impairment, restructuring and other special charges recognized in Q3 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income in Q3 2022 was $1.68 billion compared with</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> $1.88 billion i</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">n Q3 2021. Operating margin percent, defined as operating income as a percent of revenue, was 24.2%, which includes a negative impact of approximately 90 basis points attributed to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other expense was $111.0 million in Q3 2022 compared with other expense of $635.9 million in Q3 2021. The reduction in other expense was primarily driven by a charge of $405.2 million related to the repurchase of higher-cost debt in Q3 2021 as well as lower net losses on investments in equity securities in Q3 2022 compared with Q3 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate was 7.3% in Q3 2022 compared with 10.9% in Q3 2021. The effective tax rate in Q3 2022 was impacted favorably by the implementation of the provision in the Tax Cuts and Jobs Act (the 2017 Tax Act) that requires capitalization and amortization of research and development expenses for tax purposes starting in 2022 and the intangible asset impairment charge. The effective tax rate in Q3 2021 reflected the tax impact of the charge related to the repurchase of higher-cost debt, partially offset by a net discrete tax detriment.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;5</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">In Q3 2022, net income and earnings per share (EPS) were $1.45 billion and $1.61, respectively, compared with $1.11&#160;billion and $1.22 in Q3 2021. Q3 2022 EPS was </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.06</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D and development milestone charges compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.17</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q3</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2021</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_10"></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Third-Quarter Non-GAAP Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis, Q3 2022 gross margin increased 3% to $5.49 billion compared with Q3 2021. Gross margin as a percent of revenue was 79.0% in both periods as lower realized prices and increased expenses due to inflation and logistics costs were offset by favorable product mix, including the impact of lower sales of Olumiant for the treatment of COVID-19, and the favorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating income on a non-GAAP basis increased $116.9 million, or 6%, to $2.01 billion in Q3 2022 compared with Q3 2021. Operating margin percent was 28.9% on a non-GAAP basis, which includes a negative impact of approximately 90 basis points attributed to acquired IPR&#38;D and development milestone charges.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The effective tax rate on a non-GAAP basis was 10.7% in Q3 2022 compared with 14.3% in Q3 2021. The effective tax rate for Q3 2022 reflects the favorable tax impact related to the implementation of the 2017 Tax Act.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">On a non-GAAP basis in Q3 2022, net income and EPS were $1.79 billion and $1.98, respectively, compared with $1.61 billion and $1.77 in Q3 2021. Q3 2022 non-GAAP EPS was </font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">inclusive of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.06</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> of acquired IPR&#38;D and development milestone charges compared with </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">$0.17</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> in </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Q3</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">2021</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For further detail on non-GAAP measures, see the reconciliation below as well as the &#34;Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)&#34; table later in this press release.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;6</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="12" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Quarter</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">2021</font></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">% Change</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">32%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring and other special charges</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Amortization of intangible assets</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses on investments in equity securities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Charge related to repurchase of higher-cost debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Partial reversal of COVID-19 antibodies inventory charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(.11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.98</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">1.77</font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">12%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:100%">Numbers may not add due to rounding.</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestone charges</font></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.06&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.17&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(63)%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;7</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_22"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Selected Revenue Highlights</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:180%">(Dollars in millions)</font></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Third Quarter</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Year-to-Date</font></div></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Selected Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">% Change</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Trulicity</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,850.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,600.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5,503.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">4,588.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">COVID-19 antibodies</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">386.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">217.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">78%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,985.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,176.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">69%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Taltz</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">679.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">593.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,774.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,565.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Verzenio</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">617.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">335.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">84%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,675.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">945.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">77%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">447.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">626.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(29)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,512.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,851.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(18)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(c)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">573.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">390.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">47%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,453.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,058.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">37%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">238.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">286.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(17)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">785.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">923.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(15)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Cyramza</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">232.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">253.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(8)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">693.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">762.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(9)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Alimta</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">119.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">457.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(74)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">691.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">1,626.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(58)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">(d)</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">182.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">406.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(55)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">624.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">809.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(23)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">193.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">192.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">558.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">650.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(14)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Emgality</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">168.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">140.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">475.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">415.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Forteo</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">177.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">200.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(12)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">453.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">617.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(27)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tyvyt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">76.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">125.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(39)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">235.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">340.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">(31)%</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Mounjaro</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">187.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">203.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Retevmo</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">40.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">33.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">127.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">76.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">67%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Total Revenue</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,941.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">6,772.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">21,239.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">20,318.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="36" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab, and were made pursuant to EUAs or similar regulatory authorizations </font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Humalog includes Insulin Lispro</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Jardiance includes Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">, Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> and Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> XR</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> Olumiant includes sales</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%"> of </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">baricitinib that were made pursuant to EUA or similar regulatory authorizations</font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM &#8211; not meaningful</font></div></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;8</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Trulicity</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Trulicity revenue was $1.85 billion, an increase of 16% compared with Q3 2021. U.S. revenue increased 18% to $1.42 billion, driven by increased demand, partially offset by lower realized prices. The lower realized prices were driven by unfavorable segment mix and higher contracted rebates, partially offset by changes to estimates for rebates and discounts. Revenue outside the U.S. was $432.0 million, an increase of 8%, driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Taltz</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Taltz revenue increased 15% compared with Q3 2021 to $679.9&#160;million. U.S. revenue increased 17% to $493.8&#160;million, driven by increased demand, partially offset by lower realized prices. Revenue outside the U.S. increased 9%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">to $186.1 million, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Verzenio</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Verzenio revenue increased 84% compared with Q3 2021 to $617.7 million. U.S. revenue was $414.8 million, representing an increase</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">of $215.1 million compared with Q3 2021, driven by increased demand. Revenue outside the U.S. was $202.9 million, an increase of 49%, driven by increased demand, partially offset by lower realized prices due to the impact of the NRDL formulary in China and the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Humalog</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Humalog revenue decreased 29% compared with Q3 2021 to $447.0 million. Revenue in the U.S. decreased 29% to $248.1 million, driven by unfavorable segment mix and list price reduction of Insulin Lispro injection. Revenue outside the U.S. decreased 29% to $198.8 million, driven by lower realized prices due to the impact of VBP in China and the unfavorable impact of foreign exchange rates.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;9</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Jardiance</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's worldwide Jardiance revenue for Q3 2022 was $573.3 million, an increase of 47% compared with Q3 2021. U.S. revenue increased 59% to $350.9 million, primarily driven by increased demand and changes to estimates for rebates and discounts. Revenue outside the U.S. was $222.4 million, an increase of 31%, primarily driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Alimta</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Alimta revenue decreased 74% compared with Q3 2021 to $119.4 million. U.S. revenue decreased 78% to $64.6&#160;million, driven by decreased demand due to the entry of multiple generics in Q2 2022. Revenue outside the U.S. decreased 66% to $54.8 million, largely driven by decreased demand due to generic competition.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company expects continued volume and revenue decline for Alimta as a result of generic competition due to the loss of patent exclusivity in major markets. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Olumiant</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Olumiant revenue decreased 55% compared with Q3 2021 to $182.9 million. U.S. revenue decreased 88% to $22.9 million, driven by a decline in utilization for COVID-19 treatment. Revenue outside the U.S. was $160.0 million, a decrease of 25%, driven by the unfavorable impact of foreign exchange rates and a decline in utilization for COVID-19 treatment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Emgality</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, Emgality generated worldwide revenue of $168.5 million, an increase of 20% compared with Q3 2021. U.S. revenue was $114.0 million, an increase of 14%, driven by increased </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;10</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">demand. Revenue outside the U.S. was $54.6 million, an increase of 36%, primarily driven by increased demand, partially offset by the unfavorable impact of foreign exchange rates. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Tyvyt</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, the company's Tyvyt revenue in China was $76.8 million, a decrease of 39% compared with Q3 2021, driven by the impact of the NRDL formulary in China, which resulted in lower realized prices that were partially offset by increased volume, as well as increased competitive pressure.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Tyvyt is part of the company's alliance with Innovent. Lilly reports total sales of Tyvyt made by Lilly as revenue, with payments made to Innovent for its portion of the gross margin reported as cost of sales. Lilly also reports as revenue a portion of the gross margin for Tyvyt sales made by Innovent.&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">Mounjaro</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">For Q3 2022, worldwide Mounjaro revenue was $187.3 million. U.S. revenue was $97.3 million. Revenue outside the U.S. was $90.0 million, driven by revenue related to a sales collaboration agreement with Mitsubishi Tanabe Pharma for the right to sell and distribute Mounjaro in Japan. </font></div><div><font><br></font></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_28"></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%;text-decoration:underline">2022 Financial Guidance </font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company has updated certain elements of its 2022 financial guidance on both a reported and non-GAAP basis. EPS for 2022 is now expected to be in the range of $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis. The reductions in the reported and non-GAAP EPS ranges both reflect the unfavorable impact of foreign exchange rates as well as the $0.06 EPS impact associated with acquired IPR&#38;D and development milestone charges in Q3 2022. The company's 2022 financial guidance reflects adjustments shown in the reconciliation table below. </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;11</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:61.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.169%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.339%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2022<br>Expectations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">% Change vs 2021</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (reported)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$6.50 to $6.65</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">6% to 9%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Net losses on investments in equity securities</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.52</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.51</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">Asset impairment, restructuring, and other special charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">.17</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per share (non-GAAP)</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">$7.70 to $7.85</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">4% to 6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:8pt;font-weight:400;line-height:140%">Numbers may not add due to rounding</font></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestone charges</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$.67</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company now anticipates 2022 revenue to be between $28.5 billion and $29.0 billion. This includes an additional $300 million of unfavorability from foreign exchange rates since the company's previous guidance update, for a total impact of approximately $1.0 billion of unfavorability from foreign exchange rates for the full year. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's outlook for gross margin, marketing, selling and administrative expenses, and research and development expenses remains unchanged. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Acquired IPR&#38;D and development milestone charges are now expected to be approximately $670 million, reflecting total charges in the first nine months of the year. There have been no material acquired IPR&#38;D and development milestone charges recognized to date in the fourth quarter and this financial guidance does not include any impact from potential or pending business development transactions in the fourth quarter of the year, including the company's pending acquisition of Akouos.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Operating margin percent on a reported basis has been reduced by 100 basis points and is now expected to be approximately 26%, driven by the intangible asset impairment for GBA1 Gene Therapy (PR001). Operating margin percent on a non-GAAP basis remains unchanged at approximately 29%.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;12</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Other income (expense) for 2022 is now expected to be expense in the range of $600 million to $700 million on a reported basis and is still expected to be expense in the range of $0 to $100 million on a non-GAAP basis. The company's updated reported guidance reflects the impact of net losses on investments in equity securities during Q3 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The company's financial results for Q3 2022 include the favorable impact related to the implementation of the provision of the 2017 Tax Act that requires capitalization and amortization of research and development expenses for tax purposes. The company's financial guidance for reported and non-GAAP tax rates of approximately 13% to 14% continues to assume this provision of the 2017 Tax Act will be deferred or repealed by Congress effective for 2022. If this provision of the 2017 Tax Act is not deferred or repealed by Congress effective for 2022, the company still expects the reported and non-GAAP tax rates to be approximately 10% to 11%.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Based on these changes, the company has lowered reported EPS guidance by $0.46 to now be in the range of $6.50 to $6.65 and lowered non-GAAP EPS guidance by $0.20 to now be in the range of $7.70 to $7.85. The reductions in the reported and non-GAAP EPS ranges both reflect the unfavorable impact of foreign exchange rates as well as the $0.06 EPS impact associated with acquired IPR&#38;D and development milestone charges in Q3 2022. The reduction in reported EPS guidance also reflects the impact of the intangible asset impairment for GBA1 Gene Therapy (PR001) as well as additional net losses on investments in equity securities during Q3 2022.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;13</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">The following table summarizes the company's updated 2022 financial guidance&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:44.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:100%">2022 Guidance</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Updated</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$28.8 to $29.3 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$28.5 to $29.0 billion</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 76%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Gross Margin % of Revenue (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 78%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Marketing, Selling &#38; Administrative</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.4 to $6.6 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.1 to $7.3 billion</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Acquired IPR&#38;D &#38; Development Milestones</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. $610 million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. $670 million</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(600) to $(500) million</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(700) to $(600) million</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Other Income&#47;(Expense) (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$(100) million to $0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 13% to 14%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.96 to $7.11</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$6.50 to $6.65</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Earnings per Share (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.90 to $8.05</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">$7.70 to $7.85</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin % (reported)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 27%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 26%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Operating Margin % (non-GAAP)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Approx. 29%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:100%">Non-GAAP guidance reflects adjustments presented in the earnings per share table above.</font></td></tr></table></div><div style="margin-top:5pt"><font><br></font></div><div style="margin-top:5pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;14</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_31"></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Webcast of Conference Call</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">As previously announced, investors and the general public can access a live webcast of the Q3 2022 financial results conference call through a link on Lilly's website at investor.lilly.com&#47;webcasts-and-presentations. The conference call will begin at 9 a.m. Eastern time today and will be available for replay via the website.</font></div><div><font><br></font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">Non-GAAP Financial Measures</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Certain financial information for 2022 and 2021 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add due to rounding. Reported results were prepared in accordance with U.S. generally accepted accounting principles (GAAP) and include all revenue and expenses recognized during the periods. Non-GAAP measures reflect adjustments for the items described in the reconciliation tables later in the release. The press release and related materials provide certain GAAP and non-GAAP figures excluding the impact of foreign exchange rates. Lilly recalculates current period figures on a constant currency basis by keeping constant the exchange rates from the base period. Beginning in 2022, presentations of non-GAAP financial measures will not include adjustments for upfront charges and development milestones related to acquired IPR&#38;D. Non-GAAP financial measures for Q3 2021 have been adjusted to reflect this updated presentation. The company's 2022 financial guidance is being provided on both a reported and a non-GAAP basis. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:700;line-height:180%">About Lilly</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly unites caring with discovery to create medicines that make life better for people around the world. We&#8217;ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47</font><font style="color:#4472c4;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world&#8217;s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer&#8217;s disease, providing solutions to some of the most debilitating immune system disorders, and </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;15</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we&#8217;re motivated by one thing&#58; making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit</font><font style="color:#212121;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">Lilly.com and Lilly.com&#47;newsroom.</font><font style="color:#1f497d;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%"> </font><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:180%">F-LLY</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Statement Regarding Forward-Looking Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words &#34;estimate&#34;, &#34;project&#34;, &#34;intend&#34;, &#34;expect&#34;, &#34;believe&#34;, &#34;target&#34;, &#34;anticipate&#34; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated, including the impact of the evolving COVID-19 pandemic or any future pandemic, epidemic, or similar public health threat and the global response thereto&#59; uncertainties related to the company's efforts to develop, manufacture, and distribute potential treatments for COVID-19&#59; the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals&#59; the impact and outcome of acquisitions and business development transactions and related integration costs&#59; the expiration of intellectual property protection for certain of the company's products and competition from generic and&#47;or biosimilar products&#59; the company's ability to protect and enforce patents and other intellectual property&#59; changes in patent law or regulations related to data package exclusivity&#59; competitive developments affecting current products and the company's pipeline&#59; market uptake of recently launched products&#59; information technology system inadequacies, breaches, or operating failures&#59; unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in the company's information technology systems, networks, and facilities, or those of third parties with whom the company shares its data&#59; unexpected safety or efficacy concerns associated with the company's products&#59; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured&#59; issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of demand, labor shortages, third-party performance, or regulatory actions related to our facilities&#59; reliance on third-party relationships and outsourcing arrangements&#59; regulatory changes or other developments&#59; regulatory actions regarding currently marketed products&#59; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals&#59; devaluations in foreign currency exchange rates or changes in interest rates, and inflation&#59; changes in tax law, tax rates, or events that differ from the company's assumptions related to tax positions&#59; asset impairments and restructuring charges&#59; the impact of global macroeconomic conditions, trade disruptions, global disputes, unrest, war, or other costs, uncertainties and risks related to engaging in business in foreign jurisdictions&#59; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC)&#59; and regulatory compliance problems or government investigations. For additional information about the factors that could cause actual results or events to differ materially from forward-looking statements, please see the company's latest Form 10-K and subsequent Forms 8-K and 10-Q filed with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;#</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Alimta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (pemetrexed disodium, Lilly)</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;16</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:103.68pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Basaglar</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin glargine injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cymbalta</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (duloxetine, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Cyramza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (ramucirumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Emgality</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (galcanezumab-gnlm, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Forteo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (teriparatide of recombinant DNA origin injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Glyxambi</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;linagliptin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humalog</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (insulin lispro injection of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Humulin</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (human insulin of recombinant DNA origin, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Jardiance</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(empagliflozin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Mounjaro</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (tirzepatide injection, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Olumiant</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (baricitinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Qbrexza</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (glycopyrronium cloth, Dermira)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Retevmo</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (selpercatinib, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Synjardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (empagliflozin&#47;metformin, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Taltz</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(ixekizumab, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trijardy</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> XR (empagliflozin&#47;linagliptin&#47;metformin hydrochloride extended release tablets, Boehringer Ingelheim)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Trulicity</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(dulaglutide, Lilly)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Tyvyt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (sintilimab injection, Innovent)</font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Verzenio</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> (abemaciclib, Lilly)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Third party trademarks used herein are trademarks of their respective owners.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;17</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_34"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating Results (Unaudited) &#8211; REPORTED</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:31.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">% Chg.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,941.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6,772.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">21,239.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">20,318.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,579.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,430.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,081.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,262.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(3)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,802.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,705.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,194.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,032.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Marketing, selling and administrative</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,614.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,577.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,797.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,839.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(1)%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and development milestones</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">62.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">177.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(65)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">668.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">532.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">26%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">206.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">206.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">211.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(2)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,676.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,881.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(11)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,290.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,439.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net interest income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(61.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(76.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(210.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(240.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(49.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(559.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(370.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">116.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(111.0)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(635.9)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(83)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(580.9)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(124.3)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">NM</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,565.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,245.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,710.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,315.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">9%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">113.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(16)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">402.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">460.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(12)%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,451.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,110.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">31%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,307.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">3,855.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">32%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4.76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid per share</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">.85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding (thousands) - diluted</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">903,782&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">910,751&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">904,480&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">911,656&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">NM &#8211; not meaningful</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;18</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_37"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.685%"><tr><td style="width:1.0%"></td><td style="width:21.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.481%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September&#160;30, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September&#160;30, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,579.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(124.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,455.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,430.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,421.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">206.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(206.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(111.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">107.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(635.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">628.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">113.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">100.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">214.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">135.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">133.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">268.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,451.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">337.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,789.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1,110.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">504.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1,614.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.22</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.55&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.&#160;</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;19</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the three months ended September&#160;30, 2022, include the following&#58; </font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:39.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(124.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(124.1)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(206.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(206.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">107.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">107.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">100.8</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">98.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">82.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">337.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.37</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude net losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-28.84pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily the intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the three months ended September&#160;30, 2021, include the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:24.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization </font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of Debt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(137.1)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">128.1&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(9.0)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">223.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">628.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">133.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">108.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">176.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">320.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(101.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">504.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.55</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> net losses</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%"> on investments in equity securities. </font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude charge related to the repurchase of higher-cost debt.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude partial reversal of COVID-19 antibodies inventory charge.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;20</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><div id="i98ce0abc448f4f99903a91460bfdd3e1_40"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.333%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.341%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Eli Lilly and Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="33" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September&#160;30, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Nine Months Ended</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">September&#160;30, 2021</font></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">GAAP Reported</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</font></div></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP Adjusted</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td></tr><tr style="height:8pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,081.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(450.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,631.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">5,262.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(771.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,491.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">206.5</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(206.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">211.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(580.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">602.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(124.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">156.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">402.9</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">272.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">675.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">460.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">232.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">692.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">4,307.1</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">986.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5,293.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">3,855.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">907.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">4,763.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">4.76</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">1.09&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">4.23</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.99&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">5.22&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.12pt">The company uses non-GAAP financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (GAAP). The company's non-GAAP measures adjust reported results to exclude amortization of intangibles and other items that are typically highly variable, difficult to predict, and of a size that could have a substantial impact on the company's reported operations for a period. The company believes that these non-GAAP measures provide useful information to investors. Among other things, they may help investors evaluate the company's ongoing operations. They can also assist in making meaningful period-over-period comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these non-GAAP measures in addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;21</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.08pt">Adjustments to certain GAAP reported measures for the nine months ended September&#160;30, 2022, include the following&#58; </font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:39.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(450.0)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(450.0)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(206.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(206.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">602.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">602.4</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">93.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">129.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">272.7</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">356.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">473.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">986.2</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">1.09</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude net losses on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-28.84pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily the intangible asset impairment for GBA1 Gene Therapy (PR001) due to changes in estimated launch timing.</font></div><div style="margin-bottom:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;22</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:1pt solid #666666;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.02pt">Adjustments to certain GAAP reported measures for the nine months ended September&#160;30, 2021, include the following&#58;</font></div><div style="margin-bottom:3pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.452%"><tr><td style="width:1.0%"></td><td style="width:24.070%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.865%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(ii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of Debt</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iii)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other specified items</font><font style="color:#000000;font-family:'Garamond',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(iv)</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Total </font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(395.0)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(376.4)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(771.4)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment, restructuring and other special charges</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(211.6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">(211.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(248.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">405.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">156.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(48.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">85.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">114.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">232.0</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">313.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(199.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">320.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">474.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">907.6</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">(0.22)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:700;line-height:100%">0.99</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:36pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">Numbers may not add due to rounding.</font></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The table above reflects only line items with non-GAAP adjustments.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-22.47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">i.</font><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-24.76pt"><font style="background-color:#ffffff;color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude net gains on investments in equity securities.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.05pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude charge related to the repurchase of higher-cost debt.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-27.15pt"><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18pt">Exclude primarily net inventory charges related to COVID-19 antibodies, an intangible asset impairment resulting from the sale of the rights to Qbrexza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Garamond',serif;font-size:10pt;font-weight:400;line-height:120%">, and acquisition and integration costs recognized as part of the closing of the acquisition of Prevail Therapeutics Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #666666;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:6pt;padding-left:32.62pt;padding-right:32.62pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;23</font></div></td></tr></table></div><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140056208680064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY AND COMPANY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Stock (no par value)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">7 1/8% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">1.625% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">2.125% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">0.625% Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">6.77% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">1.700% Notes due 2049</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member', window );">0.500% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">1.625%&#160;Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">1.125% Notes due 2051</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">1.375% Notes due 2061</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A500NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>lly-20221101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20221101"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20221101.xsd" xlink:type="simple"/>
    <context id="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="if91f3e5334174e1f83766d429987c39e_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A500NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl80L2ZyYWc6NDViNTI3ZWIxZGYyNDQzM2JlMjI0YmY0NjRjMzQ2ZGQvdGFibGU6YmQyN2FhOWU4NjllNDkwNzk2MmIwYTgzZjdlOTk5ODkvdGFibGVyYW5nZTpiZDI3YWE5ZTg2OWU0OTA3OTYyYjBhODNmN2U5OTk4OV8yLTEtMS0xLTE1OTU1MQ_7102fcb9-83d5-4721-8f83-cd86d2189407">0000059478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl80L2ZyYWc6NDViNTI3ZWIxZGYyNDQzM2JlMjI0YmY0NjRjMzQ2ZGQvdGFibGU6YmQyN2FhOWU4NjllNDkwNzk2MmIwYTgzZjdlOTk5ODkvdGFibGVyYW5nZTpiZDI3YWE5ZTg2OWU0OTA3OTYyYjBhODNmN2U5OTk4OV81LTEtMS0xLTE1OTU1MQ_daffb7ee-8079-43b5-ab0b-7a057b1cf9ee">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg1_090d1364-9878-4786-b7b0-65b187276702">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xNTk_357f041e-efb9-41c8-8862-265929f470e6">2022-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg2_4946831b-11a3-4d38-b12e-1e18564053a3">ELI LILLY AND COMPANY</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6ZTE5MmNmM2M2YmVjNDExYWJmNTAxMDFhZmEzNmYwYTEvdGFibGVyYW5nZTplMTkyY2YzYzZiZWM0MTFhYmY1MDEwMWFmYTM2ZjBhMV8wLTAtMS0xLTE1OTU1MQ_80631658-2fa4-46fd-8f30-8153899f626a">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6ZTE5MmNmM2M2YmVjNDExYWJmNTAxMDFhZmEzNmYwYTEvdGFibGVyYW5nZTplMTkyY2YzYzZiZWM0MTFhYmY1MDEwMWFmYTM2ZjBhMV8wLTItMS0xLTE1OTU1MQ_44ed8091-8477-4a05-aa76-5953ff2ea133">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6ZTE5MmNmM2M2YmVjNDExYWJmNTAxMDFhZmEzNmYwYTEvdGFibGVyYW5nZTplMTkyY2YzYzZiZWM0MTFhYmY1MDEwMWFmYTM2ZjBhMV8wLTQtMS0xLTE1OTU1MQ_792f45b2-3b54-4081-9616-663df6023556">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8wLTAtMS0xLTE1OTU1MQ_dc6b0d25-8eaf-4097-8543-d9e884f25597">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8xLTAtMS0xLTE1OTU1MQ_171b3d79-1ea8-430f-8eab-7ad379647c85">Indianapolis,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8xLTEtMS0xLTE1OTU1MQ_cb0325cf-4a74-41fe-9748-9c2ffaa0d03b">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzI4MzE3NGM2ODk1NDA3N2I4MDVhMWFjNGJlZWE3NzIvdGFibGVyYW5nZTo3MjgzMTc0YzY4OTU0MDc3YjgwNWExYWM0YmVlYTc3Ml8xLTItMS0xLTE1OTU1MQ_578f57e3-1149-4b44-9ac6-5748f9359690">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg3_4cded068-0a5d-49b7-b357-eea52fab644a">317</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg4_0f831128-9b47-4762-a67d-c2efff94aac6">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NTBiY2JjMDUzODcwNGNhOThiNjRmMTUzZWM1Y2Y2YzUvdGFibGVyYW5nZTo1MGJjYmMwNTM4NzA0Y2E5OGI2NGYxNTNlYzVjZjZjNV8wLTAtMS0xLTE1OTU1MQ_4d2df7e8-773d-4ab3-8461-ad9d12ba2a2a">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NzBhZGRhOTdkZTgwNGVlNDljZjI1YWZhNTNjYjZhZTcvdGFibGVyYW5nZTo3MGFkZGE5N2RlODA0ZWU0OWNmMjVhZmE1M2NiNmFlN18wLTAtMS0xLTE1OTU1MQ_04777cac-0e9b-47d5-8b90-60f35ed35d11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6MzExYTcyM2VjZTM2NDAyZmFiOWJjNzdjZTk5MGNhYzUvdGFibGVyYW5nZTozMTFhNzIzZWNlMzY0MDJmYWI5YmM3N2NlOTkwY2FjNV8wLTAtMS0xLTE1OTU1MQ_ece5ed03-a862-4539-bd71-c88f5be96ef2">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NGQ1MDBkZmIzNzJiNGM1ZTgwMzc3NzU4ZDFhY2UyMjAvdGFibGVyYW5nZTo0ZDUwMGRmYjM3MmI0YzVlODAzNzc3NThkMWFjZTIyMF8wLTAtMS0xLTE1OTU1MQ_5c46353b-015a-4d4d-b6d6-9e69edfe8418">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xLTAtMS0xLTE1OTU1MQ_e43c8ab6-187c-4089-b647-603e2284a20e">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xLTItMS0xLTE1OTU1MQ_f7215f31-b9c9-428e-8118-6f20c0c613e9">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia0bb182376cd42f5bc285a9943459472_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xLTQtMS0xLTE1OTU1MQ_f472e356-7935-4fb2-92bf-b630d5d341fa">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8yLTAtMS0xLTE1OTU1MQ_1832c58e-a581-4c1e-a4f2-544613245e25">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8yLTItMS0xLTE1OTU1MQ_dabfae72-ebf5-49cd-8732-040cbd839ba7">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ice1b6a2781a345fa9cde7f64925d50f4_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8yLTQtMS0xLTE1OTU1MQ_0f3ebd20-1360-4c87-9f44-14c3c8609410">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8zLTAtMS0xLTE1OTU1MQ_e29633e9-1505-49a8-bf7e-297c69921510">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8zLTItMS0xLTE1OTU1MQ_433392e8-191e-46eb-97c9-298168de444f">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie630494001b54db78dbf0db05ea85aad_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8zLTQtMS0xLTE1OTU1MQ_8707c7ff-b8af-467f-95cb-618a333abed6">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if91f3e5334174e1f83766d429987c39e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV80LTAtMS0xLTE1OTU1MQ_147c660b-8fc6-46e6-9cf4-cae5298c7738">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if91f3e5334174e1f83766d429987c39e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV80LTItMS0xLTE1OTU1MQ_fa0dbf96-ed45-45d5-ac8f-d7cceccc60c5">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if91f3e5334174e1f83766d429987c39e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV80LTQtMS0xLTE1OTU1MQ_94420cbc-e54c-436b-95b8-9fed5a4808d8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV81LTAtMS0xLTE1OTU1MQ_ffdf3854-6211-48ba-920e-58d01767d68d">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV81LTItMS0xLTE1OTU1MQ_4c381bab-2d95-474a-893a-15f5489e47dc">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6c49a3e3bc534f468afc9270f7988f14_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV81LTQtMS0xLTE1OTU1MQ_6a9cc135-38fc-40d3-9065-a18f93fdf7f9">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV82LTAtMS0xLTE1OTU1MQ_80563eda-5a20-4ddf-ba0f-9217f4f2368b">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV82LTItMS0xLTE1OTU1MQ_2731b356-b828-4475-b389-e8b09a8493b9">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4d9dae0f31df40efafcef2f51f910ec7_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV82LTQtMS0xLTE1OTU1MQ_272eb06f-868b-4493-8670-6b5138be7288">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV83LTAtMS0xLTE1OTU1MQ_2b9ba470-ec09-427a-9834-0970cfdb8240">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV83LTItMS0xLTE1OTU1MQ_de6a0f24-b3d6-454c-b722-2b8a706d8a45">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia74a8dc1ffe049c18d2a4d45d287b477_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV83LTQtMS0xLTE1OTU1MQ_9a4a4810-0e91-47c1-a63f-7d912f2f3ed9">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV84LTAtMS0xLTE1OTU1MQ_7211a67f-8948-473d-8290-0a1605ddcf1c">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV84LTItMS0xLTE1OTU1MQ_5a86633f-7f2a-4678-8bbe-ed332a9d4129">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie89711d4b9924397bcd2f10211dd925b_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV84LTQtMS0xLTE1OTU1MQ_cf020ac7-fa2b-448c-bc3f-d51c9f04f82c">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV85LTAtMS0xLTE1OTU1MQ_a8d94290-4518-4465-a504-d9a588748a96">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV85LTItMS0xLTE1OTU1MQ_df75e0b1-a57a-41ae-a34e-31eb4c01644d">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i01d1e4662b24470f9261b39274545e0b_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV85LTQtMS0xLTE1OTU1MQ_9b5e5d08-0051-41fd-a111-9316d9bb2971">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMC0wLTEtMS0xNTk1NTE_9ac3c1f2-b9c4-4c49-8c3c-648130c30e6c">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMC0yLTEtMS0xNTk1NTE_550ca458-dbfd-43f1-b2d7-35f6012c18ed">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i08297cf93ac2497099da5c4f8cbbea55_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMC00LTEtMS0xNTk1NTE_11803921-0321-4707-b08c-d4d71fb0d9e7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMS0wLTEtMS0xNTk1NTE_42fc72be-ec91-4b74-a5d4-738cfc82114c">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMS0yLTEtMS0xNTk1NTE_1ca3df82-97db-44ba-809a-bad2febfbbce">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifd26c28b556044fdba6bdd7cccc06b79_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGFibGU6NDNmNTc3YTFkY2JkNDYxN2IwOGM1Nzc0ZWY4OWE5ZjEvdGFibGVyYW5nZTo0M2Y1NzdhMWRjYmQ0NjE3YjA4YzU3NzRlZjg5YTlmMV8xMS00LTEtMS0xNTk1NTE_17188bbe-a694-4109-b218-37116f593fc7">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmNhOTE3ZTNiYjc5ZTQzYWI4MDY5ODlmYzA4YWMxMTNmL3NlYzpjYTkxN2UzYmI3OWU0M2FiODA2OTg5ZmMwOGFjMTEzZl8xL2ZyYWc6MWRlOGJhZmRlYTNiNDg3OTk2N2ZkYWU5NzUzODg3OWYvdGV4dHJlZ2lvbjoxZGU4YmFmZGVhM2I0ODc5OTY3ZmRhZTk3NTM4ODc5Zl8xMTg5_e6f8e183-1fe1-40fb-af96-14c7afce9a9b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M&B%=<0 Y')P<WH7O'\QZY:H*EWEMG@$XG!; X;0!#@? X30&#HV2/DCE;_&
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
M8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSA
MR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB
M0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>
M@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&
M8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%
M=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#5
M2?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7
M>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;
MIJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=Y
MYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNH
MR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \
M& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH
M=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z
M@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^
M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !W.&%5!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M '<X856#L[[.[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( '<X85697)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ =SAA533W
M>[3W!@  %#$  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( '<X856?H!OPL0(  .(,   -
M  "  3D/  !X;"]S='EL97,N>&UL4$L! A0#%     @ =SAA59>*NQS
M$P(   L              ( !%1(  %]R96QS+RYR96QS4$L! A0#%     @
M=SAA51E%%?4W 0  )P(   \              ( !_A(  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( '<X854D'INBK0   /@!   :              "
M 6(4  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( '<X
M855ED'F2&0$  ,\#   3              "  4<5  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  )$6      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>12</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lly-20221101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lly-20221101.htm">lly-20221101.htm</File>
    <File>lly-20221101.xsd</File>
    <File>lly-20221101_def.xml</File>
    <File>lly-20221101_lab.xml</File>
    <File>lly-20221101_pre.xml</File>
    <File>q322lillysalesandearningsp.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lly-20221101.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 12,
   "dts": {
    "definitionLink": {
     "local": [
      "lly-20221101_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lly-20221101.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20221101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20221101_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20221101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 38,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 10,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20221101",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221101.htm",
      "contextRef": "ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.lilly.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lly-20221101.htm",
      "contextRef": "ife000743c8704e3e9f50a9b1485b0e4e_D20221101-20221101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 11,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due June 2, 2026 [Member]",
        "label": "1.625% Notes Due June 2, 2026 [Member]",
        "terseLabel": "1.625% Notes due 2026"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.700% Notes due 2049 [Member]",
        "label": "1.700% Notes due 2049 [Member]",
        "terseLabel": "1.700% Notes due 2049"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.125% Notes due 2051",
        "label": "1.125% Notes due 2051 [Member]",
        "terseLabel": "1.125% Notes due 2051"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2061",
        "label": "1.375% Notes due 2061 [Member]",
        "terseLabel": "1.375% Notes due 2061"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625%\u00a0Notes due 2043",
        "label": "1.625%\u00a0Notes due 2043 [Member]",
        "terseLabel": "1.625%\u00a0Notes due 2043"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.125% Notes Due June 3, 2030 [Member]",
        "label": "2.125% Notes Due June 3, 2030 [Member]",
        "terseLabel": "2.125% Notes due 2030"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A500NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2033",
        "label": ".500% Notes due 2033 [Member]",
        "terseLabel": "0.500% Notes due 2033"
       }
      }
     },
     "localname": "A500NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "label": "6.77%\u00a0Notes Due January\u00a01, 2036 [Member]",
        "terseLabel": "6.77% Notes due 2036"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": ".625% Notes due 2031 [Member]",
        "label": ".625% Notes due 2031 [Member]",
        "terseLabel": "0.625% Notes due 2031"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "label": "7 1/8% Notes Due June\u00a01, 2025 [Member]",
        "terseLabel": "7 1/8% Notes due 2025"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20221101",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Stock (no par value)"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lilly.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000059478-22-000248-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000059478-22-000248-xbrl.zip
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MCSS'11ADP[S\5IJPA3':1M!X"-HF"=F24";?4N._N]3F05D@.]/ +&_\^_+
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MX=H?^</O<?KAU_$:S,>9.87_.D6ON_C_4$L#!!0    ( '<X857F AD+LP,
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M7'X/ND?<VKD%=AO/VRY:/@G1_-Z1C)$<81?-F)/!0^=);O0?6:[RNW#]8[S
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MS[-[G+R'CV]>;2ZW+^U_M'KSZG]02P,$%     @ =SAA54 @B7C@$   WZ0
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M?BV577CTU6CKKW?V^<5J?GNWL+O7/A;6-0^[*(K:J"5*4:)$O$3YW;')K@;
M/Q'>]2'6$X"KS'US*HQMG+XY&=P/WC_8\P/>FV8PY,T#]>/2C/7L/DPU&/KY
M$9_JL<C7<C'"8_%MFCW(B_*%U_ZW[33E0"W.M)IGZ[KWH-HO:[LT=N,M:T,G
M<_/\PO\V,W8^^W&YGJ^_7OMUKY"+5[[#E_^Q7V?<8FL99X Z20'%@H+,H?)'
M*ES&)**.S-8/#_7,+L&O[W?S5Y-TS' 18=OZB$8+N\KO"_UM=;M=-"U9?K4J
MU[?L:BEO[>I.;CMXF&4@L$'^8@,RV:),*IB)Q_G]U3>3^A"Y.#\]BXDQD^L:
MED49#N3%8^MSW6W]-WVM//#*])75ES?YIRO?]ZH,N\I?0/E+):OC(UX=O'DO
MBQU.6>@.GK<MKG3N8YV[-:A17L:&@0:M\\#W?4.=G_8BR0MC"Q^_-IC0\/R]
M-,:_^:OM/]Z)6#13&"%N$ ),4 VH8@Y()PV "F%&)4/&R#@Q-\PR44%O(3[=
M_9*48).W2QLK["9B0\4]D*YQ!![/5 ^AMS Q0.Q-HXXL^!;##D7?UCA.^(O%
MU]E+Y&7\)E_;U0_W%D.&?K:WRA8SDF'!5<H!RD0&*"'6[S^A!(02P[@23'(:
M(ON6.:8F>G3I8?XEJ8 FYMXF)=0PI;<QV:[S$_%S9I4W4I/\OL'Y?\,Y,MOL
M2;7U/S=7M<FF\C@%N\, $C;.T#>LW!U"L$I\?-?6<Q2'%P!]Y^Y"FO9Q=GQ_
M1$JVCY^B0AEA!$BIM( R(D&FA *$4"-@BHUR)MS9-<XQ/6?G8?[E/[]#'/[7
M_B-*28R:F^D,\7B#23J[QSO&3R^WUTQ4C-L;3-AH;B_ZP8KT?:U,M/J^YIXC
M^KY6Z'7?U]ZTC^^[W!ORG_=+BSU#?/LD"L'\;LZFP&ED (69!9GF$ACNH)..
M*9/"< _8,M,T_6!ME<8\1MEMK(8XPA-Q-8H[W-+DD28EU 0_K>CJY1';>(OQ
MBR?B;U3OV)O'2$\9P$VKOVSK/Z+7##"C[CM#.L3GR#X4LOSX]_W76Y4O9@Y:
MQ5,?)%I*":"&";]!S@@@B"K$,X,R)D+S8K61I^8AM^"2#;KPS%>=KNYL5V\2
MSNSZ NV/RF<UVMHKAU4?:;2\5:,!^[FJY@9]$],_S1?VS7VU-G#)(:2( 412
MOU<S2 "9(>0#%XTTRA1-LZ!(I6GPJ4EOFUPM 28;A+&)YSWB0O/-_>@8)\T<
MPD2/Q/*AR0/RR7N#C9Q&/C3C,'O<T"9>E._SQ5S/UU[?/TNO@[E<S 1-#559
M"BRF E"A$!!>C(!*F^$444MY\')X./S4A/D-8;*#&*[,!O:ZM3F,DS.K,X:.
M*'D>M[J70!N&&TVBQTW9%VE+JUY;_A3"*A V519!;/=7&5="62@!<]S'KBBE
M0#(O6R>HHLX8(U%$OK-YDJE)MH)9W^A3$;5A;>8R:(\_F*&S;^\;R.FWK6]F
M*6I'/YBMT3;SO5B+W<2WTM&^?V_N.N;6O17\HUU[>]N^>X=72YT7=WE1/0SO
M_3-AK_/[Y;KX>IT;.X,$0:ZD!&G&?;1BO%.46&B0IMIB)C)H#([;3K3.-S6O
MN(VK:YB?)A5J3W.R19Z4T&.W'NV\A^Y&3L;F.!N4043VV+D$T3-@,],^_LC[
MFR!C#[<\8=WZA%<DW?N,AN^*&9C%0@@E@<9& 6I5"C)!,=!,"\RQR?S_PJ.K
MQCFFYD;0I8=97PEY5.E,,Y,AL=5@?LX>6C50TRNT:N8H)K(:S-5H@57,XQ09
M3[62T!I.-?<<,9IJA5X/IMJ;#BP0?I>OUG+QO_.[:BE'A#ME20JTCY4 948"
MD9:?(DL.L;$*,=BO0K@VS=1<WN/"UPW8Q*/M%2TU,AL:) WE:YS8*)JJ_B7"
MC4P,KQ&N#_OG% DWFG:T2KBY=9S\[U?@1LJ[V?5"KE9OW?MUKO_X(;^5\^5,
M2.FTTAQ@CE) N=- 0.4 08XYC6B*4="',<>GF)KL*X1)[I(*8_+[!F7@.M["
M9+O43\//F64>2TVPO+NM;Y"VDRM58=_VWNC;+M:KW2O?A-XRP2@B[S9P)_"
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MNSUGN^8>WZYE>4H79DU C+)Q5 9I#CK 8$R.3901#;D#_//YB,03&E<CGUK
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ME2<?29"$\83\-Z$AO"#-L *J77+0Q0U8)-!H5K4#;4JJ=D*-9@%>,,1G0/!
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MZ=M%"0_Y>CZ=)CZ09 [&>8I]"0<KE6H5GVJ% ZWB4T^,3_6.%9]2H285:FI
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M$0D]#_)3EF/*/8QQ9]H+2_HD",4>D,2J'1$L\X)(J.641T)T9Z'<P!&]X7R
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M6Z9+0*%RC;*?/-TV*)9$1%-X;5Y2Y,FOMK5>C7>7!(J1PM==K23*,*(1PPX
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M<LS69,;L]XT-S*XUO49>JJB4TR/W<>37-2-&HU)L-JMERQWP0Z;8?%3I&F/
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M]UCYRG\ 2SJ'_TSBJ??C_P]02P$"% ,4    " !W.&%5])S[P+L?  !&%P$
M$               @ $     ;&QY+3(P,C(Q,3 Q+FAT;5!+ 0(4 Q0    (
M '<X857F AD+LP,  /L1   0              "  >D?  !L;'DM,C R,C$Q
M,#$N>'-D4$L! A0#%     @ =SAA5;H( '@F"@  RDP  !0
M ( !RB,  &QL>2TR,#(R,3$P,5]D968N>&UL4$L! A0#%     @ =SAA54 @
MB7C@$   WZ0  !0              ( !(BX  &QL>2TR,#(R,3$P,5]L86(N
M>&UL4$L! A0#%     @ =SAA55-+[4R^"0  7%$  !0              ( !
M-#\  &QL>2TR,#(R,3$P,5]P<F4N>&UL4$L! A0#%     @ =SAA59:($1++
M7P  .>D% !X              ( !)$D  '$S,C)L:6QL>7-A;&5S86YD96%R
@;FEN9W-P+FAT;5!+!08     !@ & (X!   KJ0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
